BioStack Raises $9.5M Seed Led by Peak XV

TL;DR: BioStack, a healthcare data startup, announced a $9.5 million seed round on October 22, 2026, led by Peak XV with Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures and Y Combinator. It plans to sell de-identified hospital data to AI developers and researchers. The sources reviewed give no valuation.

BioStack, a San Francisco-based healthcare technology company, announced the round on October 22, 2026, according to its press release on PR Newswire. YourStory reported that Peak XV led the $9.5 million seed round, alongside the other investors named above.

The announcement is also a product launch. The company says it is starting a data network across the U.S., India, Brazil and Argentina. The release was distributed as a paid press release, according to Yahoo Finance, so the product claims below are the company's own and have not been independently checked.

What does BioStack actually sell?

BioStack sells de-identified patient data, stitched together across hospitals, to AI developers, biotech companies and researchers. The company says its network covers over 100 million de-identified patient records in the four countries it named.

The problem it targets is real. Per the same release, patient histories and clinical data are often fragmented across hospitals, providers and technology systems, which leaves clinicians without a complete picture of a patient's treatment. BioStack's answer is to connect notes, labs, imaging, medications, treatments and outcomes into one record per patient. Medspark describes three buyers for the resulting datasets: researchers who want treatment histories tied to long-term outcomes, AI developers who want multimodal training and evaluation sets, and the company's own research partners.

CEO Sanat Mishra put it this way in the company's statement, as YourStory quoted him: the company is building the infrastructure that connects all of the clinical information and makes it useful for clinicians today and for the researchers and AI developers building medicine's future.

Who put money in, and what does the cap table say?

The investor list pairs a lead with a regional focus alongside two specialist funds and some of the best-known early-stage names. The sources I reviewed give no check sizes, so the table shows only who took part.

Item	What was reported
Amount	$9.5 million seed
Lead	Peak XV
Other investors	Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures, Y Combinator
Stated use of funds	U.S. and international expansion, platform development, engineering and research hiring
Valuation	Not given in the sources reviewed

A long list of institutional names tells you who judged the idea credible. It says nothing about whether hospitals will keep signing data agreements or whether AI developers will keep paying for the output. For a plain explanation of what a seed round normally buys, see startup funding rounds explained in specific numbers.

Can an individual investor get into this round?

Nothing in the reporting describes an offering for outside investors. The round was announced with the institutions above, so the practical question is whether deals like this reach angel groups or syndicates later, and at what price. Preference Model's seed round raised the same question about AI-adjacent rounds, and AI Foundation Model Startup Funding: Sequoia 2026 covers how those later rounds tend to price.

What are the risks?

Medspark's own assessment is blunt. Per that report, de-identification is legally delicate and technically imperfect, hospital data-sharing deals move slowly, and several well-funded competitors are chasing the same clinical corpus.

Weigh those three points. The record count is a company claim, and a large number of records does not mean the data is clean, usable for training, or licensed for every purpose a buyer might want.

What should you watch next?

Watch for named hospital or health-system partners, because the sources describe a multi-country network without naming who supplies the data. Watch for named buyers among AI and biotech companies, since paying customers are what turn a data asset into revenue. And watch for a follow-on round. That is where a price gets put on whatever progress the company makes. For a smaller comparable, read Peppermint's seed round led by Moxxie.

Common mistakes when reading a seed announcement

The first mistake is treating a paid press release as reporting. The numbers in it came from the company, and outlets that repeat it add no verification.

The second is reading investor names as proof of traction. A prominent lead signals a bet, and seed-stage bets lose more often than they win.

The third is assuming you can buy in. Most seed rounds like this one close with institutions and never open to individuals.

FAQ

Who led BioStack's seed round?

Peak XV led the $9.5 million seed round, according to YourStory and the company's release. Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures and Y Combinator also took part.

What does BioStack do?

BioStack connects clinical information from separate health systems into longitudinal patient records. It then builds de-identified datasets that AI developers, biotech companies and researchers can use to train and test medical AI models.

What valuation did BioStack raise at?

None of the sources reviewed gives a valuation, so any figure you see elsewhere is unverified here. Check the company's own announcement or a regulatory filing before relying on one.

Can accredited investors invest in BioStack?

The reporting describes a round with institutional investors and does not mention an offering for outside investors. Any future access would likely come through a later round, an angel group or a syndicate.

Your next step

Before you give any weight to this deal, find the company's own release and read which claims are the company's and which are an outlet's. Then write down the one fact that would change your mind, such as a named hospital partner or a paying AI customer, and check for it at the next funding announcement.

Educational content only. Not investment, tax, or legal advice. Not an offer or solicitation to buy or sell securities. Past performance does not guarantee future results. Private-market investments are illiquid and involve risk of loss, including total loss of capital. Consult qualified advisers. Angel Investors Network is not a broker-dealer or investment adviser.